The poster will, present the results of the two clinical studies carried out in collaboration with German CRO Bioskin in Hamburg and Charité University Hospital in Berlin and other related data. The latest study evaluated the hair growth promoting effects of FOL-005 on alopecia patients.
"The exposure gained by Follicum from presenting at the conference provides a good opportunity to expand the scientific, clinical, business and patient-related networks," says CEO Jan Alenfall. Follicum's founder Professor Anna Hultgårdh Nilsson will participate and Jan Alenfall will present the poster during the conference.
Details on the scientific program: https://www.barcelonahair2019.org/scientific-program
Poster Session
Title: FOL-005 - modulation of hair growth in clinical studies
Poster number: P050
For further information, please contact:
Jan Alenfall - CEO, Follicum AB
Telephone: +46 46 19 21 97
Email: info@follicum.com
About Follicum AB
Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.